ADHD Medications for Perimenopausal Brain Fog: Early Evidence and Limits

ADHD medications may ease some daily challenges linked to perimenopausal brain fog, but the evidence is preliminary and hasn’t shown better performance on standard cognitive tests. That gap matters: people may feel more capable in the demands of everyday life even when short lab tasks show no measurable change. The distinction also complicates how researchers judge whether a treatment is helping. A test can measure a specific skill under controlled conditions; it may not capture how someone manages competing demands across an ordinary day.

At the Menopause Society’s recent annual meeting, Pallavi Khanna, M.D., and coauthors presented a review of the research on ADHD drugs for perimenopausal executive dysfunction. Khanna, a professor of obstetrics and gynecology at the University of Tennessee Health Sciences College of Medicine, describes the findings as “promising but early.” That wording sets the right expectation: the studies raise a question for researchers, but they don’t establish that these drugs reliably treat brain fog. The evidence base is especially limited because it comes from just three small trials.

Why researchers are looking at ADHD treatments

Executive dysfunction can affect planning, focus, working memory, and the ability to shift between tasks. It overlaps with symptoms associated with ADHD, and hormonal changes may help explain the connection. That overlap makes it worth asking whether treatments used for ADHD might help some people who develop similar difficulties during perimenopause. It doesn’t, by itself, show that the two conditions have the same cause or that one medication will work for everyone experiencing brain fog.

Khanna says both conditions have been linked to changes involving the prefrontal cortex, which supports executive function. Dopamine and norepinephrine help regulate its activity, while estradiol, the most potent form of estrogen, supports dopamine signaling. As estradiol levels fall during perimenopause, some people experience difficulties with concentration, memory, and organization. ADHD medications affect dopamine and norepinephrine, making them a plausible subject for study. Plausible, though, isn’t the same as proven: a biological explanation can guide research without settling whether a treatment improves daily functioning.

The symptoms are common: the Menopause Society estimates that 40 to 60% of women report cognitive symptoms during perimenopause. Their intensity can shift with hormonal fluctuations, and symptoms may ease after menopause. Yet, Khanna says, there’s no FDA-approved treatment specifically for this brain fog, and hormone therapy’s cognitive effects are inconsistent. That leaves clinicians weighing symptoms in context: cognitive complaints may occur alongside other perimenopause symptoms, but the article describes no single treatment that resolves them for everyone. The range of experiences matters.

What the small trials suggest

The review found only three small trials, all conducted by the same research group. In those studies, lisdexamfetamine (Vyvanse) and atomoxetine (Strattera) improved participants’ self-reported sense of functioning. The trials did not find corresponding gains on objective cognitive tests. The result is a split signal: participants reported feeling better able to function, while the tests used in the studies didn’t register an improvement. With so few trials, that difference is a reason to investigate further, not a firm basis for drawing broad conclusions.

Khanna sees a possible explanation in what each measure captures. A brief test in a quiet lab checks performance on a narrow task; everyday executive function means keeping up with work, family responsibilities, and interruptions over much longer stretches. Self-report measures may reflect those demands more closely, while small studies and tests that are too short or easy may miss modest changes. (And this is the part most people overlook.) A person’s sense of improved functioning is meaningful, but it doesn’t tell researchers on its own which abilities changed, how consistently they changed, or whether the effect would hold up in a larger study. The findings also linked more ADHD symptoms with worse menopause symptoms overall, another association that calls for careful interpretation.

Where medication fits in care

Khanna doesn’t recommend ADHD medication as a general response to perimenopausal brain fog. She would first assess other possible contributors, including sleep problems, and consider hormone therapy when other perimenopause symptoms make it appropriate. This reflects a practical problem: concentration and memory complaints can sit alongside other symptoms, so a clinician needs to consider the whole picture rather than treat one complaint as proof of ADHD. If cognitive complaints continue, or a patient screens positive for ADHD symptoms, she says she would refer her for a psychiatric evaluation and a decision about medication.

That approach also keeps the limits of the current research in view. The studies described in the review don’t establish that a person with perimenopausal brain fog has ADHD, or that an ADHD medication is an appropriate choice without further assessment. If you’re working in this space, the gap between self-reported benefit and test performance is a useful reminder to ask what “improvement” means to patients and how studies can measure it. Here’s the thing: daily function is difficult to reduce to a short score, but a subjective report alone can’t answer every research question.

What researchers still need to learn

For now, the research points to a possible treatment path worth studying, not an established answer. Larger trials and measures that reflect daily demands will be needed to determine whether ADHD medications offer reliable benefits for perimenopausal executive dysfunction. Studies would also need to clarify whether the reported gains appear consistently across participants, given that the existing evidence comes from three small trials by one research group. The numbers here are underwhelming, but the mismatch between reported function and test results gives researchers a specific issue to examine.

That work could help distinguish a real change in everyday functioning from a result that appears only on one kind of measure. It could also show whether the apparent benefit applies to a defined group of patients or is too variable to support a general approach. Until those questions are answered, the evidence supports further study and individual clinical assessment. Not a settled treatment recommendation.